Policy Briefs on THE
ECONOMIC IMPACT OF HIV
Brief 13: Assessing Cost Effectiveness Across HIV and Health Interventions
By Markus Haacker, Kate Harris, Gesine Meyer-Rath
November 2021
Key Points
- While other criteria may also be taken into account, decision support on choices between health interventions typically focuses on cost-effectiveness in terms of health gains per monetary unit spent.
- Comparisons between HIV interventions and other health-related interventions require common measures of health gains. The most common are the disability-adjusted life year (DALY) and the quality-adjusted life year (QALY).
- Socio-economic considerations often come in only indirectly, e.g., in the form of cost-effectiveness thresholds derived from an economic valuation of health gains or reflecting a country’s fiscal context.
Summary Briefs
The summary briefs provide an overview of three main areas of economic impact.
Master Slide Set
Policy Briefs
The policy briefs provide more detail on the evidence available on each of the topics.
1. The State of Programme Implementation to Reduce HIV Transmission & Aids-Related Mortality
2. Increased Health and Life Prospects and Their Economic Valuation
3. HIV, Population Dynamics and the Labour Force
4. Human Capital
5. Capital and Investment
6. Productivity and Employment of People Living with HIV
7. Economic Growth – Overview
8. Interactions Between HIV and Poverty
9. Disease Burden Across Population Sub-Groups
10. Trade-offs between Allocation to Health and Other Sectors
11. Domestic Public Funding for HIV
12. Trade-offs and Synergies between HIV and Other Health Objectives
13. Assessing Cost Effectiveness Across HIV and Health Interventions
14. External and Domestic Health Financing, and the Role of Public vs. Private Domestic Health Funding
15. Public and Private Provision of Health and HIV Services
16. Trade-offs within the HIV Budget
17. The Economics of HIV and of HIV Programmes in the Era of Covid-19
Brief 13: Assessing Cost Effectiveness Across HIV and Health Interventions
By Markus Haacker, Kate Harris, Gesine Meyer-Rath
November 2021
Key Points
- While other criteria may also be taken into account, decision support on choices between health interventions typically focuses on cost-effectiveness in terms of health gains per monetary unit spent.
- Comparisons between HIV interventions and other health-related interventions require common measures of health gains. The most common are the disability-adjusted life year (DALY) and the quality-adjusted life year (QALY).
- Socio-economic considerations often come in only indirectly, e.g., in the form of cost-effectiveness thresholds derived from an economic valuation of health gains or reflecting a country’s fiscal context.
Technical Briefs
The technical briefs provide more detail on the evidence available on each of the topics.
1. The State of Programme Implementation to Reduce HIV Transmission & Aids-Related Mortality
2. Increased Health and Life Prospects and Their Economic Valuation
3. HIV, Population Dynamics and the Labour Force
4. Human Capital
5. Capital and Investment
6. Productivity and Employment of People Living with HIV
7. Economic Growth – Overview
8. Interactions Between HIV and Poverty
9. Disease Burden Across Population Sub-Groups
10. Trade-offs between Allocation to Health and Other Sectors
11. Domestic Public Funding for HIV
12. Trade-offs and Synergies between HIV and Other Health Objectives
13. Assessing Cost Effectiveness Across HIV and Health Interventions
14. External and Domestic Health Financing, and the Role of Public vs. Private Domestic Health Funding
15. Public and Private Provision of Health and HIV Services
16. Trade-offs within the HIV Budget
17. The Economics of HIV and of HIV Programmes in the Era of Covid-19
Wits Health Consortium, University of the Witwatersrand